Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.9), the stock would be worth ₹20.76 (20% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.8 | ₹17.24 |
0%
|
| 3-Year Average | 0.9 | ₹20.76 |
+20%
|
| 5-Year Average | 1 | ₹21.26 |
+23%
|
| Industry Average | 2.2 | ₹48.92 |
+184%
|
| Country Average | 2.3 | ₹49.88 |
+189%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
|
744.4m INR | 0.8 | -4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 4.5 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 3.6 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 3.7 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 7.3 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.6 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 1.5 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.3 |
| Median | 2.3 |
| 70th Percentile | 4.2 |
| Max | 4 185.7 |
Other Multiples
Bharat Immunologicals and Biologicals Corporation Ltd
Glance View
Bharat Immunologicals & Biologicals Corp. Ltd. is a biotechnology company, which engages in the manufacture and market of pharmaceutical products. The company is headquartered in Bulandshahr, Uttar Pradesh. The firm is primarily engaged in the manufacture of Oral polio Vaccine, Zinc Tablets, Diarrhea management Kit and BIB Sweet Tablets. The company is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The firm is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). The company is also diversified into Plasma-derived medicines and Oral Cholera vaccines. The firm's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.
